<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: September 19, 1997 Commission File No. 0-27352
------------------ -------
(Date of earliest event reported)
HYBRIDON, INC.
--------------
(Exact name of registrant as specified in its Charter)
Delaware 04-3072298
-------- ----------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
620 Memorial Drive, Cambridge, Massachusetts 02139
- -------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
(617) 528-7000
--------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
On September 19, 1997, Hybridon, Inc. issued a press release announcing
its scheduled delisting from the Nasdaq National Market. A copy of the press
release has been filed with this Current Report on Form 8-K as Exhibit 99.1 and
is incorporated herein by reference.
ITEM 7. EXHIBITS
99.1 Press release dated September 19, 1997.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: September 19, 1997 HYBRIDON, INC.
/s/ E. Andrews Grinstead, III
---------------------------------------
E. Andrews Grinstead, III
Chairman, President and Chief Executive
Officer
<PAGE> 4
INDEX TO EXHIBITS
EXHIBIT
NO. DESCRIPTION
- ------- -----------
99.1 Press release dated September 19, 1997.
<PAGE> 1
EXHIBIT 99.1
HYBRIDON NEW RELEASE
<TABLE>
<S> <C> <C>
Hybridon, Inc. Tel: 617-528-7000 Fax: 617-528-7001
FOR IMMEDIATE RELEASE 620 Memorial Drive www.hybridon.com
Cambridge, MA 02139
CONTACT: DOUGLAS J. JENSEN
Vice President, Administration and
Corporate Development
617-528-7523
</TABLE>
HYBRIDON ANNOUNCES SCHEDULED DELISTING FROM
THE NASDAQ NATIONAL MARKET
Cambridge, Mass. - September 19, 1997 - Hybridon, Inc. (Nasdaq: HYBN) today
announced that it has been advised by the Nasdaq Stock Market, Inc. ("NASDAQ")
that because the Company was not in compliance with the continued listing
requirements of The Nasdaq National Market. NASDAQ has determined that the
Company is no longer eligible for continued listing on The Nasdaq National
Market. The Company's securities are currently scheduled to be delisted from
The Nasdaq Stock Market effective with the close of business on September 25,
1997.
The Company intends to appeal the decision to NASDAQ's appeal panel and to
request a delay in delisting until final resolution by the appeal panel. In
addition, NASDAQ has recently adopted new continued listing requirements and
the Company is currently exploring methods for complying with one of the new
requirements.
If the Company's appeal is unsuccessful and the Company's Common Stock is
delisted from The Nasdaq National Market, the Company intends to make
application for listing on the Nasdaq Small Cap Market. The delisting of the
Company's Common Stock from The Nasdaq National Market may adversely affect the
liquidity of the Company's Common Stock and the ability of the Company to raise
capital.
Hybridon, headquartered in Cambridge, Massachusetts, is a leader in the
discovery and development of novel medicines for the treatment of important
diseases, based primarily on antisense technology. Antisense technology
involves the use of synthetic segments of DNA and RNA to stop the production of
disease-associated proteins by interacting at the genetic level with target
strands of messenger RNA.
# # #
LEADERSHIP IN GENETIC ANTISENSE MEDICINE
